Journal Mobile Options
Table of Contents
Vol. 67, No. 4, 2013
Issue release date: May 2013
Neuropsychobiology 2013;67:224-229
(DOI:10.1159/000347090)

A Pilot Study of Anterior Cingulate Cortex Neurochemistry in Adolescents with Generalized Anxiety Disorder

Strawn J.R. · Chu W.-J. · Whitsel R.M. · Weber W.A. · Norris M.M. · Adler C.M. · Eliassen J.C. · Phan K.L. · Strakowski S.M. · DelBello M.P.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: This study used proton magnetic resonance spectroscopy (1H MRS) to evaluate the neurochemistry of the anterior cingulate cortex (ACC) in adolescents with generalized anxiety disorder (GAD). Methods: Adolescents with GAD (n = 10) and healthy subjects (n = 10) underwent a 1H MRS scan at 4 T. Glutamate (Glu), N-acetyl aspartate, creatine (Cr) and myo-inositol concentrations were measured in the ACC and were compared between untreated adolescents with GAD and age- and sex-matched healthy subjects. Results: Glu/Cr ratios in the ACC correlated with the severity of both generalized anxiety symptoms on the Pediatric Anxiety Rating Scale and with total anxiety symptom severity as measured by the Hamilton Anxiety Rating Scale, but did not differ between adolescents with GAD and healthy subjects. In addition, no differences in N-acetyl aspartate, Cr, or myo-inositol were detected between groups. Conclusion: These findings suggest that Glu/Cr in untreated adolescents with GAD may relate to the severity of anxiety symptoms and raise the possibility that dysregulation of Glu within the ACC may be linked to the pathophysiology of pediatric GAD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Ialongo N, Edelsohn G, Werthamer-Larsson L, Crockett L, Kellam S: The significance of self-reported anxious symptoms in first-grade children. J Abnorm Child Psychol 1994;22:441-455.
  2. Ialongo N, Edelsohn G, Werthamer-Larsson L, Crockett L, Kellam S: The significance of self-reported anxious symptoms in first grade children: prediction to anxious symptoms and adaptive functioning in fifth grade. J Child Psychol Psychiatry 1995;36:427-437.
  3. Foley DL, Goldston DB, Costello EJ, Angold A: Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountains Study. Arch Gen Psychiatry 2006;63:1017-1024.
  4. Jacobson CM, Muehlenkamp JJ, Miller AL, Turner JB: Psychiatric impairment among adolescents engaging in different types of deliberate self-harm. J Clin Child Adolesc Psychol 2008;37:363-375.
  5. Pine DS, Cohen P, Gurley D, Brook J, Ma Y: The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 1998;55:56-64.
  6. Bittner A, Goodwin RD, Wittchen HU, Beesdo K, Hofler M, Lieb R: What characteristics of primary anxiety disorders predict subsequent major depressive disorder? J Clin Psychiatry 2004;65:618-626.
  7. Beesdo K, Knappe S, Pine DS: Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am 2009;32:483-524.
  8. Beesdo K, Pine DS, Lieb R, Wittchen HU: Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry 2010;67:47-57.
  9. Strawn JR, Wehry AM, DelBello MP, Rynn MA, Strakowski SM: Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety 2012;29:328-339.
  10. Beesdo K, Lau JYF, Guyer AE, McClure-Tone EB, Monk CS, Nelson EE, Fromm SJ, Goldwin BA, Wittchen H-U, Leibenluft E, Ernst M, Pine DS: Common and distinct amygdala-function perturbations in depressed versus anxious adolescents. Arch Gen Psychiatry 2009;66:275-285.
  11. Monk CS, Nelson EE, McClure EB, Mogg K, Bradley BP, Leibenluft E, Blair RJ, Chen G, Charney DS, Ernst M, Pine DS: Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Am J Psychiatry 2006;163:1091-1097.
  12. McClure EB, Monk CS, Nelson EE, Parrish JM, Adler A, Blair RJ, Fromm S, Charney DS, Leibenluft E, Ernst M, Pine DS: Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry 2007;64:97-106.
  13. Monk CS, Telzer EH, Mogg K, Bradley BP, Mai X, Louro HM, Chen G, McClure-Tone EB, Ernst M, Pine DS: Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. Arch Gen Psychiatry 2008;65:568-576.
  14. Strawn JR, Bitter SM, Adler CM, Chu W, Eliassen JC, Whitsel R, Weber WA, Cerullo MA, Strakowski SM, DelBello MP: Neurocircuitry of generalized anxiety disorder in adolescents: a pilot functional magnetic resonance and functional connectivity study. Depress Anxiety 2012;29:939-947.
  15. Cerullo MA, Adler CM, DelBello MP, Strakowski SM: The functional neuroanatomy of bipolar disorder. Int Rev Psychiatry 2009;21:314-322.
  16. Strakowski SM, Eliassen JC, Lamy M, Cerullo MA, Allendorfer JB, Madore M, Lee JH, Welge JA, DelBello MP, Fleck DE, Adler CM: Functional magnetic resonance imaging brain activation in bipolar mania: evidence for disruption of the ventrolateral prefrontal-amygdala emotional pathway. Biol Psychiatry 2011;69:381-388.
  17. Etkin A, Egner T, Kalisch R: Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011;15:85-93.
  18. Allman JM, Hakeem A, Erwin JM, Nimchinsky E, Hof P: The anterior cingulate cortex. The evolution of an interface between emotion and cognition. Ann NY Acad Sci 2001;935:107-117.
  19. Yamasaki H, LaBar KS, McCarthy G: Dissociable prefrontal brain systems for attention and emotion. Proc Natl Acad Sci USA 2002;99:11447-11451.
  20. Phan KL, Fitzgerald DA, Cortese BM, Seraji-Bozorgzad N, Tancer ME, Moore GJ: Anterior cingulate neurochemistry in social anxiety disorder: 1H MRS at 4 Tesla. Neuroreport 2005;16:183-186.
  21. Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ: Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004;43:1146-1153.
  22. Yüksel C, Öngür D: Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010;68:785-794.
  23. Yücel M, Wood SJ, Wellard RM, Harrison BJ, Fornito A, Pujol J, Velakoulis D, Pantelis C: Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Aust NZ J Psychiatry 2008;42:467-477.
  24. Strawn JR, Patel NC, Chu W-J, Lee JH, Adler CM, Kim MJ, Bryan H, Alfieri DC, Welge JA, Blom TJ, Nandagopal JJ, Strakowski SM, DelBello MP: Glutamatergic effects of divalproex in manic adolescents: a proton magnetic resonance spectroscopy study. J Am Acad Child Adolesc Psychiatry 2012;51:642-651.
  25. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS: A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 2006;146:137-147.
  26. Gasparovic C, Yeo R, Mannell M, Ling J, Elgie R, Phillips J, Doezema D, Mayer AR: Neurometabolite concentrations in gray and white matter in mild traumatic brain injury: an 1H-magnetic resonance spectroscopy study. J Neurotrauma 2009;26:1635-1643.
  27. Geller B, Zimerman B, Williams M, Bolhofner K, Craney JL, DelBello MP, Soutullo C: Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. J Am Acad Child Adolesc Psychiatry 2001;40:450-455.
  28. Andreasen NC, Endicott J, Spitzer RL, Winokur G: The family history method using diagnostic criteria: reliability and validity. Arch Gen Psychiatry 1977;34:1229-1235.
  29. Crovitz HF, Zener K: A group-test for assessing hand- and eye-dominance. Am J Psychol 1962;75:271-276.
  30. Duke PM, Litt IF, Gross RT: Adolescents' self-assessment of sexual maturation. Pediatrics 1980;66:918-920.
  31. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 2002;41:1061-1069.
  32. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
  33. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R: Preliminary studies of the reliability and validity of the Children's Depression Rating Scale. J Am Acad Child Adolesc Psychiatry 1984;23:191-197.
  34. Lee J-H, Garwood M, Menon R, Adriany G, Andersen P, Truwit CL, Ugurbil K: High contrast and fast three-dimensional magnetic resonance imaging at high fields. Magn Reson Med 1995;34:308-312.
  35. Gruetter R, Boesch C: Fast, noniterative shimming of spatially localized signals. In vivo analysis of the magnetic field along axes. J Magn Reson 1992;96:323-334.
  36. Tkac I, Staruck Z, Choi IY, Gruetter R: In vivo 1H NMR spectroscopy of rat brain at 1ms echo time. Magn Reson Med 1999;41:649-656.
  37. Provincher SW: Estimation of metabolite concentration from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
  38. Grachev ID, Apkarian AV: Anxiety in healthy humans is associated with orbital frontal chemistry. Mol Psychiatry 2000;5:482-488.
  39. Bedard MJ, Chatal S: Brain magnetic resonance spectroscopy in obsessive-compulsive disorder: the importance of considering subclinical symptoms of anxiety and depression. Psychiatry Res 2011;192:45-54.
  40. Walker DL, Rattiner LM, Davis M: Group II metabotropic Glu receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci 2002;116:1075-1083.
  41. Fontanez-Nuin DE, Santini E, Quirk GJ, Porter JT: Memory for fear extinction requires mGluR5-mediated activation of infralimbic neurons. Cereb Cortex 2011;21:727-735.
  42. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ: Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic Glu receptors. J Pharmacol Exp Ther 1998;284:651-660.
  43. Shekhar A, Keim SR: LY354740, a potent group II metabotropic Glu receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000;39:1139-1146.
  44. Strawn JR, Sakolsky DJ, Rynn MA: Psychopharmacologic treatment of anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am 2012;21:527-539.
  45. Sakolsky D, Nurmi E, Birmaher B, March J, Walkup J, Piacentini J, Kendall P, Albano AM, Compton S, Sherill J, Rynn M, Ginsburg G, Badashova K, McCracken J: Association of GRIK4 with treatment response in the Child/Adolescent Anxiety Multimodal Study (CAMS). Am Acad Child Adolesc Psychiatry Annu Meet, Toronto, 2011.
  46. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD: Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008;33:1603-1610.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50